检索结果-南通市图书馆

Acrylamide inhibits nerve sprouting induced by botulinum toxin type a

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neural Regeneration Research 2014年第16期9卷 1525-1531页

作者： Hong Jiang Yi Xiang Xingyue Hu Huaying Cai Department of Neurology Sir Run Run Shaw Hospital School of Medicine Zhejiang University Second Clinical Medical College Zhejiang Chinese Medical University

botulinum toxin type a is a potent muscle relaxant that blocks the transmission and release of acetylcholine at the neuromuscular junction. Intramuscular injection of botulinum toxin type a has served as an effective and safe therapy for strabismus and focal dystonia. However, muscular weakness is temporary and after 3-4 months, muscle strength usually recovers because function- al recovery is mediated by nerve sprouting and reconstruction of the neuromuscular junction. Acrylamide may produce neurotoxic substances that cause retrograde necrotizing neuropathy and inhibit nerve sprouting caused by botulinum toxin type a. This study investigated whether acrylamide inhibits nerve sprouting after intramuscular injection of botulinum toxin type a. A tibial nerve sprouting model was established through local injection of botulinum toxin type a into the right gastrocnemius muscle of Sprague-Dawley rats. Following intramuscular injection, rats were given intraperitoneal injection of 3% acrylamide every 3 days for 21 days. Nerve sprout- ing appeared 2 weeks after intramuscular injection of botulinum toxin type a and single-fiber electromyography revealed abnormal conduction at the neuromuscular junction I week after intra- muscular injection of botulinum toxin type a. Following intraperitoneal injection of acrylamide, the peak muscle fiber density decreased. Electromyography jitter value were restored to normal levels 6 weeks after injection. This indicates that the maximal decrease in fiber density and the time at which functional conduction of neuromuscular junction was restored were delayed. Addition- ally, the increase in tibial nerve fibers was reduced. Acrylamide inhibits nerve sprouting caused by botulinum toxin type a and may be used to prolong the clinical dosage of botulinum toxin type a.

关键词： nerve regeneration peripheral nerve regeneration botulinum toxin type a acrylamide nerve sprouting electromyography nerve fibers neuromuscular junction single-fiber EMG fiberdensity action potential mean consecutive difference dysmyotonia neural regeneration

维普期刊数据库

Toosendanin interferes with pore formation of botulinum toxin type a in PC12 cell membrane

在线全文

学校读者我要写书评

暂无评论

Acta Pharmacologica Sinica 2006年第1期27卷 66-70页

作者： Mu-feng LI Yu-liang SHI Institute of Physiology,Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences,Shanghai 200031,China Institute of Physiology Shanghai Institutes for Biological Sciences Chinese Academy of Sciences Shanghai China

Aim:botulinum neurotoxins (BoNT) abort the process of neurotransmitter re-lease at presynaptic motor nerve terminals,causing muscle *** abilityof botulinum toxin to produce its effect is dependent on the ability of the lightchain to cleave the SNARE proteins associated with transmitter ***-cation of the light chain protease through the heavy chain-formed channel is apivotal step in the intoxication *** (TSN),a triterpenoid de-rivative extracted from a Chinese traditional medicine,has been demonstrated tobe an effective cure for experimental *** study was designed to explorethe antibotulismic mechanisms of ***:The inside-out single-channel recording patch-clamp technique was used to record the BoNT/A-in-duced currents in the presence and absence of ***:Channel formationwas delayed and the sizes of the channels were reduced in the TSN-treated PC12cell ***:The antibotulismic effect of TSN might occur viainterference with toxin translocation.

关键词： toosendanin botulinum toxin type a ion channel antibotulismic mechanism single channel recording

Different frequencies of repetitive transcranial magnetic stimulation combined with local injection of botulinum toxin type a for post-stroke lower limb spasticity:study protocol for a prospective,single-center,non-randomized,controlled clinical trial

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Neural Regeneration Research 2022年第11期17卷 2491-2496页

作者： Yang Shao Yang Yang Yong-Xin Sun Ai-Hua Xu Department of Rehabilitation Medicine the First Affiliated Hospital of China Medical UniversityShenyangLiaoning ProvinceChina

No definite consensus has currently been reached regarding the safety and efficacy of low-or high-frequency repetitive transcranial magnetic stimulation in the treatment of post-stroke muscle *** latest research indicates that when combined with local injections of botulinum toxin type a,it is more effective on post-stroke muscle spasticity than local injections of botulinum toxin type a *** designed a prospective,single-center,non-randomized,controlled clinical trial to investigate the safety and effica cy of different frequencies of repetitive transcranial magnetic stimulation combined with local injections of botulinum toxin type a in treating post-stroke lower limb muscle spasticity to determine an optimal therapeutic *** trial will enroll 150 patients with post-stroke muscle spasticity admitted to the Department of Rehabilitation Medicine at the First Affiliated Hos pital of China Medical Unive *** enrolled patients will undergo ro utine rehabilitation training and will be divided into five groups in-30 per group) according to the particular area of cerebral infa rction and treatment methods.G roup A:Patients with massive cerebral infarction will be given local injections of botulinum toxin type a and low-frequency(1 Hz)repetitive transcranial magnetic stimulation on the contralate ral side;G roup B:Patients with non-massive cerebral infarction will be given local injections of botulinum toxin type a and high-frequency(10-20 Hz) re petitive transcranial magnetic stimulation on the affected side;G roup C:Patients with massive/non-massive cerebral infarction will be given local injections of botulinum toxin type a;G roup D:Patients with massive cerebral infarction will be given low-frequency(1 Hz) repetitive transcranial magnetic stimulation on the contralate ral side;and G roup E:Patients with non-massive cerebral infa rction will be given high-frequency(10-20 Hz) repetitive transcranial magnetic stimulation on the affected ***

关键词： botulinum toxin type a exercise lower limbs muscle spasticity neural regeneration rehabilitation training repetitive transcranial magnetic stimulation stroke

维普期刊数据库

botulinum toxin type a combined with robot-assisted training for upper limb spasticity and motor function after stroke:a case report

在线全文

学校读者我要写书评

暂无评论

TMR Integrative Medicine 2020年第16期4卷 1-6页

作者： Min Zhang Hong You Yong-Ping Li Ming-Ming Wen Sino-French Department of Neurological Rehabilitation Gansu Provincial HospitalLanzhou 730000China

This study is to report the clinical experience of of botulinum toxin type a in combination with robot-assisted training on upper limb spasticity and motor function in stroke patient through a case *** patient underwent combined treatment with botulinum toxin type a and robot-assisted training of the upper limb for 3 *** was performed before and after combined treatment,and 3 months follow-up after *** following outcomes were measured:spasticity by the modified Ashworth scale,pain by the numeric rating scale,motor function by the Fugl-Meyer assessment in upper limb,and activity of daily living by the modified barthel *** combined botulinum toxin type a and robot-assisted training treatment had an obvious improvement in upper limb spasticity,pain,motor function and activity of daily *** toxin type A combined with robot-assisted training therapy is worthy of further application in patients with spastic stroke.

关键词： botulinum toxin type a Robot Spasticity Motor function Stroke

botulinum toxin type a Satisfaction in Different Neurological Disorders

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neuroscience & Medicine 2022年第1期13卷 1-16页

作者： Jasem Yousef Al-Hashel Doaa Youssry Soliman Ismail Ibrahim Ismail Samar Farouk Ahmed Department of Neurology Ibn Sina Hospital Kuwait City Kuwait Department of Medicine Faculty of Medicine Health Sciences Centre Kuwait University Kuwait City Kuwait Department of Neurology Cairo University Cairo Egypt Department of Neuropsychiatry Faculty of Medicine Minia University Minia Egypt

Background: The botulinum toxin type a (BoNT-A) is used in a wide range of neurological diseases. We aimed to study the overall patients/caregivers’ satisfaction with BoNT-A treatment in different neurological conditions. Methods: Prospective study included patients who had received at least two BoNT-A treatment sessions. They were asked to rate overall treatment satisfaction at the peak of treatment effect on a 1 to 10 scale (1 = not at all satisfied;10 = fully satisfied). Subjects with a rating of 1to3 were classified as not at all satisfied, those with a rating of 4 to7 as somewhat satisfied, and those with a rating of 8 to10 as very satisfied. Treatment satisfaction questionnaire for medicine (TSQM) was assessed at the end of observational period. Quality of life QOL was assessed before BoNT-A treatment and at the last visit. Results: The study was conducted from first April 2014 to August 2021. 548 patients were identified with mean age 43.66 ± 14.50. Most of participants 389 (71%) were female. At the end of observational period, the mean satisfaction was 7.28 ± 1.78. There was a highly significant difference (P P P = 0.001). Conclusion: Satisfaction with BoNT-A therapy for different neurological disorders is overall good. The highest patient satisfaction was observed with primary focal HH, and the least satisfaction was observed in writer’s cramp. BoNT-A therapy improved QOL.

关键词： botulinum toxin type a Satisfaction Headache Dystonia Movement Disorders Hyperhidrosis

botulinum toxin type a for treating chronic low back pain:A double blinded randomized control study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Methodology 2024年第3期14卷 119-125页

作者： Mantu Jain Shahnawaz Khan Paulson Varghese Sujit Kumar Tripathy Manaswini Mangaraj Department of Orthopaedics All India Institute of Medical SciencesBhubaneswar 751019OdishaIndia Department of Biochemistry All India Institute of Medical SciencesBhubaneswar 751019OdishaIndia

BACKGROUND Low back pain(LBP)is a prevalent issue that orthopedic surgeons frequently address in the outpatient *** can arise from various causes,with stiffness in the paraspinal muscles being a notable *** administration of botulinum toxin type a(BoNT-A)has been found to alleviate back pain by relaxing these stiff *** BoNT-A is approved for use in numerous conditions,a limited number of randomized clinical trials(RCTs)validate its efficacy specifically for treating *** To study the safety and the efficacy of BoNT-A in minimizing pain and improving functional outcomes in patients of chronic LBP(CLBP).METHODS In this RCT,adults aged 18-60 years with mechanical LBP persisting for at least six months were *** were allocated to either the Drug group,receiving 200 Ipsen Units(2 mL)of BoNT-A,or the Control group,which received a 2 mL *** a 2-month follow-up period,both groups were assessed using the Visual Analog Scale(VAS)for pain intensity and the Oswestry Disability Index(ODI)for disability at the start and conclusion of the study.A decrease in pain by 50%was deemed clinically *** The study followed 40 patients for two months,with 20 in each group.A clinically significant reduction in pain was observed in 36 *** was a statistically significant decrease in both VAS and ODI scores in the groups at the end of two ***,when comparing the mean score changes,only the reduction in ODI scores(15 in the placebo group vs 16.5 in the drug group,clinically insignificant)was statistically significant(P=0.012),whereas the change in mean VAS scores was not significant(P=0.45).CONCLUSION The study concludes that BoNT-A does not offer a short-term advantage over placebo in reducing pain or improving LBP scores in CLBP patients.

关键词： botulinum toxin type a Chronic low back pain Randomized control study Double-blinded Pain management Therapeutic efficacy

Dermal thickness,rather than drug concentration and injection speed,influences the effective area of botulinum toxin type a in the dermis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Plastic and Reconstructive Surgery 2024年第3期6卷 130-134页

作者： Yixin Sun Wangfei Mo Yunzhu Li Ruijia Dong Cheng Chen Jing Gao Nanze Yu Xiao Long Department of Plastic Surgery Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing100730China Department of Plastic and Burns Surgery West China HospitalSichuan UniversityChengdu610041China Department of Plastic and Reconstructive Surgery Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijing102218China Department of Ultrasound Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing100730China

Background:Recently,microbotulinum,a new technique that involves injecting botulinum toxin type a(BoNTA)microdroplets into superficial cutaneous tissue,has gained *** precise distribution of BoNTA in the targeted area profoundly affects *** factors may influence the effective area of BoNTA in the *** study aimed to determine the dermal distribution properties of BoNTA to guide microbotulinum ***:Ten healthy males aged 18–65 years without BoNTA treatment in the previous year were recruited to receive intradermal injections in the chest and *** was used to ensure the intradermal delivery of injections and measure the dermal *** minor iodine starch test was performed at baseline and 3 days,7 days,21 days,1 month,and 2 months after ***:All participants received intradermal *** dermis was thinner on the chest(thickness,0.20±0.03 cm)than on the back(thickness,0.39±0.07 cm)(P<0.05).An injection in the thicker dermis had a significantly smaller effective area at every follow-up *** drug concentration did not affect the effective area except at 3 days after *** speed did not influence the effective area at any follow-up ***:An injection in a thicker dermis leads to a smaller effective area for intradermal *** the BoNTA dose is the same,the drug concentration and injection speed do not matter.

关键词： botulinum toxin type a Effective area Microbotulinum

维普期刊数据库

botulinum toxin type a inhibits gastric myoelectrical activity and substance P release

在线全文

学校读者我要写书评

暂无评论

Botulinum toxin type A inhibits gastric myoelectrical activi...

Systematic evaluation of the efficacy and safety of botulinum toxin type a in the treatment of spastic cerebral palsy

中国神经科学学会第六届学术会议暨学会成立十周年庆祝大会

作者： Hou Yi-ping,Song Yan-feng,Zhang Yong-ping Lab.Neurobiology,Department of Anatomy,Lanzhou University School of Basic Medical Science Lanzhou 730000

＜正＞Classically, botulinum toxin type a （BTX-A） inhibits ACh release from cholinergic nerves in skeletal muscle. The aim of this study was to determine the effect of BTX-A on spontaneous contractions of stomachic smooth muscle. Wisear rats were divided into control group （n=15, 0.9 % sodium chloride）, 10 unit doses of BTX-A group （n=15, 10 U/kg）, 20 unit doses of BTX-A group （n=15, 20 U/kg）, 40 unit doses of BTX-A group （n=15, 0 U/kg）. Bipolar needle electrodes for recording gastric myoelectrical activity and a subserosa duct for injecting BTX-A were implanted into animals’ gastric antrum.

关键词： botulinum toxin type a gastric myoelectrical activity substance P

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Life Research 2023年第2期6卷 10-19页

作者： Yu Jiang Gang Liu Jing-Pei Ren Yi Zhao Hui-Zhong Bai Tuo Zhao Lin Xu Xiao-Hong Mu Department of Orthopedics Dongzhimen HospitalBeijing University of Chinese MedicineBeijing 100010China

Background:botulinum toxin type a(BTX-A)is a neuromuscular blocking ***-A inhibits acetylcholine release,causes neuromuscular transmission impairment,and decreases muscle ***:To explore the efficacy and safety of BTX-A injection in the treatment of spastic cerebral palsy through systematic evaluation and to provide a reference for the clinical use of ***:We used“Cerebral palsy”and“BTX-A”as the subject terms and used a combination of subject terms and free words for the *** searched 7 databases,including CNKI,Wanfang,VIP,Sinomed,PubMed,Embase,and Web of *** on the inclusion and exclusion criteria,we screened the articles by reading their titles,abstracts,and full texts and finally included relevant literature for systematic ***:A total of 93 papers were systematically evaluated,revealing that BTX-A injection treatment can effectively reduce muscle tone,increase joint mobility,improve gait and motor posture,and enhance gross motor movements in patients with spastic cerebral *** benefits of BTX-A treatment can be sustained for 3–6 months,with motor ability improvement lasting up to 1 *** BTX-A treatment with rehabilitation or external fixation therapy can enhance its ***,the effectiveness of BTX-A treatment is influenced by several factors,such as the dosage,number of injections,and patient *** reactions to BTX-A treatment are typically mild and can be relieved within 1–2 ***:BTX-A injection is relatively safe but reversible.

关键词： spastic cerebral palsy botulinum toxin type a systematic evaluation